Effects of botulinum toxin type a on mood and cognitive function in patients with parkinson's disease and depression

To analyze the effects of botulinum toxin type A (BtA) in the treatment of patients with Parkinson's disease and depression.

89 patients with Parkinson's disease and depression were assigned into control group and observation group by random number table method, of which 44 patients in the control group were treated with sertraline and 45 patients in the observation group were treated with BtA. The two groups were compared in terms of mood, cognitive function and adverse reactions.

The Hamilton Depression Self-Assessment Scale (HAMD) scores of the two groups following treatment were lower than those before treatment while the Mini-Mental State Examination (MMSE) scores were higher than those before treatment (P<0.05). The incidence rate of adverse events was 11.11% in the observation group and 29.55% in the control group (P<0.05). The Pittsburgh sleep quality index (PSQI) scores and 39-item PD Questionnaire (PDQ-39) scores after 2 and 3 months of treatment and 2 months after completion of treatment were lower than those before treatment (P<0.05).

Patients with Parkinson's disease and depression receiving BtA treatment can gain treatment effects similar to those of the sertraline, with less adverse reactions.